Impacts of Bacillus subtilis JQ61816 on lipid panel and expression of genes involved in cholesterol metabolism in hypercholesterolemic rats

Abolfazl Dehkohneh, Azam Khalili, Omid Ardalani, Amin Mohsenzadeh, Hoda Sabati, Parvaneh Jafari


Hypercholesterolemia is one of the major risk factors associated with the emergence and development of cardiovascular diseases (CVD) and atherosclerosis. The hypocholesterolemic effects of probiotics have been indicated by numerous studies. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and cytochrome P450 7A1 or cholesterol 7 alpha-hydroxylase (CYP7A1) are two important genes in choletsterol metabolism. In this study, the effects of Bacillus subtilis JQ61816 on lipid panel, hepatic enzymes and expression levels of HMGCR and CYP7A1 were investigated. Twenty-one male Wistar rats were randomly allotted to 3 experimental groups; a) negative control group (ND) fed with normal diet, b) high-fat diet group (HFD) fed with high cholesterol diet, and c) probiotic group (BS) fed with high cholesterol diet supplemented with probiotic B. subtilis. Serum analysis of treatment groups was performed to measure fasting blood sugar (FBS), lipid profile parameters, hepatic enzymes, urea, and uric acid. Our results showed that B. subtilis could reduce the level of total cholesterol, triglycerides, and LDL and it also could increase high-density lipoprotein (HDL) level. Moreover, alanine transaminase (ALT), aspartate transaminase (AST), and uric acid were significantly lower in BS group compare to HFD group. Furthermore, up-regulation of HMGCR and down-regulation of CYP7A1 were observed in BS group. The results of our study suggest that consumption of probiotic B. subtilis JQ61816 may prevent or decline the development of hypercholesterolemia and other cardiovascular diseases.


Probiotics; Bacillus subtilis; Hypercholesterolemia; Cardiovascular disease; Triglyceride


Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015; 2015:971453.

Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. circulation. 2017; 135(10):e146-e603.

World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: WHO; 2014. Available at:

Levine GN, Keaney JF, Jr., Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med. 1995; 332(8):512-21.

Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL, Wood PD. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med. 1998; 339(1):12-20.

Polychronopoulos E, Panagiotakos DB, Polystipioti A. Diet, lifestyle factors and hypercholesterolemia in elderly men and women from Cyprus. Lipids Health Dis. 2005; 4:17.

Last AR, Ference JD, Falleroni J. Pharmacologic treatment of hyperlipidemia. Am Fam Physician. 2011; 84(5):551-8.

Eghdamian B, Ghose K. Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc). 1998; 34(11):943-56.

Godlee F. Adverse effects of statins. BMJ. 2014; 348:g3306.

Azad MAK, Sarker M, Wan D. Immunomodulatory Effects of Probiotics on Cytokine Profiles. Biomed Res Int. 2018; 2018:8063647.

Dehkohneh A, Jafari P, Fahimi H. Effects of probiotic Lactobacillus paracasei TD3 on moderation of cholesterol biosynthesis pathway in rats. Iran J Basic Med Sci. 2019; 22(9):1004-9.

Ooi LG, Liong MT. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci. 2010; 11(6):2499-522.

Miraghajani M, Zaghian N, Dehkohneh A, Mirlohi M, Ghiasvand R. Probiotic Soy Milk Consumption and Renal Function Among Type 2 Diabetic Patients with Nephropathy: a Randomized Controlled Clinical Trial. Probiotics Antimicrob Proteins. 2019; 11(1):124-32.

Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol. 2003; 17(5):849-59.

Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8):506-14.

Gielen S, Landmesser U. The Year in Cardiology 2013: cardiovascular disease prevention. Eur Heart J. 2014; 35(5):307-12.

Huang Y, Zheng Y. The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the down-regulation of Niemann-Pick C1-like 1 in Caco-2 cells. Br J Nutr. 2010; 103(4):473-8.

Thobari J, Gansevoort R, De Jong P, De Jong-van Den Berg L. The effect lipid lowering drugs statins on increasing risk of albuminuria and reduce of renal function: A cohort study. Drug Safety. 2008; 31(10): 885-960-.

Davies GR. Reversible dysphasia and statins. J Korean Med Sci. 2012; 27(4):458-9.

Shehata MG, El-Sahn MA, El Sohaimy SA, Youssef MM. Role and Mechanisms Lowering Cholesterol by Dietary of Probiotics and Prebiotics: A Review. J Appl Sci. 2019; 19(8):737-46.

Fernandez ML, Roy S, Vergara-Jimenez M. Resistant starch and cholestyramine have distinct effects on hepatic cholesterol metabolism in guinea pigs fed a hypercholesterolemic diet. Nutr Res. 2000; 20(6):837-49.

Gallaher CM, Munion J, Hesslink R, Jr., Wise J, Gallaher DD. Cholesterol reduction by glucomannan and chitosan is mediated by changes in cholesterol absorption and bile acid and fat excretion in rats. J Nutr. 2000; 130(11):2753-9.

Lin Y, Meijer GW, Vermeer MA, Trautwein EA. Soy protein enhances the cholesterol-lowering effect of plant sterol esters in cholesterol-fed hamsters. J Nutr. 2004; 134(1):143-8.

Lambert JM, Bongers RS, de Vos WM, Kleerebezem M. Functional analysis of four bile salt hydrolase and penicillin acylase family members in Lactobacillus plantarum WCFS1. Appl Environ Microbiol. 2008; 74(15):4719-26.

Pereira DI, Gibson GR. Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol. 2002; 68(9):4689-93.

Liong MT, Shah NP. Acid and bile tolerance and cholesterol removal ability of lactobacilli strains. J Dairy Sci. 2005; 88(1):55-66.

De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2007; 292(1):G358-68.

Kim KP, Rhee CH, Park HD. Degradation of cholesterol by Bacillus subtilis SFF34 isolated from Korean traditional fermented flatfish. Lett Appl Microbiol. 2002; 35(6):468-72.

Heo W, Lee ES, Cho HT, Kim JH, Lee JH, Yoon SM, et al. Lactobacillus plantarum LRCC 5273 isolated from Kimchi ameliorates diet-induced hypercholesterolemia in C57BL/6 mice. Biosci Biotechnol Biochem. 2018; 82(11):1964-72.

Briand F, Sulpice T, Giammarinaro P, Roux X. Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model. Benef Microbes. 2019; 10(5):555-67.

Choi ID, Kim SH, Jeong JW, Lee DE, Huh CS, Hong SS, et al. Triglyceride-Lowering Effects of Two Probiotics, Lactobacillus plantarum KY1032 and Lactobacillus curvatus HY7601, in a Rat Model of High-Fat Diet-Induced Hypertriglyceridemia. J Microbiol Biotechnol. 2016; 26(3):483-7.

Park DY, Ahn YT, Huh CS, McGregor RA, Choi MS. Dual probiotic strains suppress high fructose-induced metabolic syndrome. World J Gastroenterol. 2013; 19(2):274-83.

Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr. 2002; 76(6):1249-55.

Ahn HY, Kim M, Chae JS, Ahn YT, Sim JH, Choi ID, et al. Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. Atherosclerosis. 2015; 241(2):649-56.

Bernini LJ, Simão AN, Alfieri DF, Lozovoy MA, Mari NL, de Souza CH, et al. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. Nutrition. 2016; 32(6):716-9.

Dong H, Rowland I, Thomas LV, Yaqoob P. Immunomodulatory effects of a probiotic drink containing Lactobacillus casei Shirota in healthy older volunteers. Eur J Nutr. 2013; 52(8):1853-63.

Ivey KL, Hodgson JM, Kerr DA, Thompson PL, Stojceski B, Prince RL. The effect of yoghurt and its probiotics on blood pressure and serum lipid profile; a randomised controlled trial. Nutr Metab Cardiovasc Dis. 2015; 25(1):46-51.

Park S, Kang J, Choi S, Park H, Hwang E, Kang YG, et al. Cholesterol-lowering effect of Lactobacillus rhamnosus BFE5264 and its influence on the gut microbiome and propionate level in a murine model. PLoS One. 2018; 13(8):e0203150.

Wang G, Huang W, Xia Y, Xiong Z, Ai L. Cholesterol-lowering potentials of Lactobacillus strain overexpression of bile salt hydrolase on high cholesterol diet-induced hypercholesterolemic mice. Food Funct. 2019; 10(3):1684-95.

Palaniyandi SA, Damodharan K, Suh JW, Yang SH. Probiotic Characterization of Cholesterol-Lowering Lactobacillus fermentum MJM60397. Probiotics Antimicrob Proteins. 2020; 12(3):1161-72.

Michael DR, Moss JW, Calvente DL, Garaiova I, Plummer SF, Ramji DP. Lactobacillus plantarum CUL66 can impact cholesterol homeostasis in Caco-2 enterocytes. Benef Microbes. 2016; 7(3):443-51.

Catry E, Pachikian BD, Salazar N, Neyrinck AM, Cani PD, Delzenne NM. Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sci. 2015; 132:77-84.

Engelking LJ, McFarlane MR, Li CK, Liang G. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J Lipid Res. 2012; 53(7):1359-68.

Yadav R, Vij R, Kapila S, Khan SH, Kumar N, Meena S, et al. Milk fermented with probiotic strains Lactobacillus rhamnosus MTCC: 5957 and Lactobacillus rhamnosus MTCC: 5897 ameliorates the diet-induced hypercholesterolemia in rats. Ann Microbiol. 2019; 69(5):483-94.

Watanabe S, Katsube T, Hattori H, Sato H, Ishijima T, Nakai Y, et al. Effect of Lactobacillus brevis 119-2 isolated from Tsuda kabu red turnips on cholesterol levels in cholesterol-administered rats. J Biosci Bioeng. 2013; 116(1):45-51.

Kumari L, Kanwar SS. Purification and Characterization of an Extracellular Cholesterol Oxidase of Bacillus subtilis Isolated from Tiger Excreta. Appl Biochem Biotechnol. 2016; 178(2):353-67.

Feng X, Hu Y, Zheng Y, Zhu W, Li K, Huang CH, et al. Structural and functional analysis of Bacillus subtilis YisP reveals a role of its product in biofilm production. Chem Biol. 2014; 21(11):1557-63.

Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, et al. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 1995; 81(5):687-93.

Xu G, Li H, Pan LX, Shang Q, Honda A, Ananthanarayanan M, et al. FXR-mediated down-regulation of CYP7A1 dominates LXRalpha in long-term cholesterol-fed NZW rabbits. J Lipid Res. 2003; 44(10):1956-62.

Singh AB, Dong B, Kraemer FB, Liu J. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet. Physiol Rep. 2020; 8(5):e14387.



  • There are currently no refbacks.

Copyright (c) 2021 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.